In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
San Diego Union Tribune
|
July 28, 2026
His father suffered from gout in silence. Now a San Diego scientist is bringing the cure home
As a child, James Mackay watched his father struggle just to stand up. “You shouldn’t have eaten this or that,”…
For more
The Wall Street Journal
|
July 23, 2026
Biotech Startup Gets $130 Million to Settle ‘Unfinished Business’
James Mackay’s previous effort to provide gout patients with a novel treatment ended in disappointment. Venture capitalists are helping him…
For more
Scrip Citeline
|
July 16, 2026
BIO 2026: Catching Up With Vaxart, Aphaia, Connect Biopharma, Kyverna And Chugai
The recent BIO International Convention offered an opportunity to check in with biopharmaceutical companies about near-term milestones and long-term strategies. Scrip spoke…
For more
Biopharma Dive
|
July 22, 2026
Crystalys nets $130M more to push gout drug through late-stage tests
Less than a year after landing a big funding round, Crystalys Therapeutics has banked a second one, announcing Wednesday a…
For more
The Wall Street Journal
|
July 16, 2026
Biotech Venture Funding Roars Back
Biotechnology venture funding is surging, driven by an explosion of mergers and acquisitions and a revival of initial public offerings in…
For more
BioXconomy
|
July 7, 2026
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial
Spinal cord injuries have devastating consequences and impact more than 15 million people worldwide. Damage to spinal nerves can lead to pain,…
For more
Fierce Biotech
|
June 26, 2026
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery
For anyone watching the GLP-1 headlines in recent years, it’s not hard to see which way the wind is blowing…
For more
Clinical Leader
|
June 9, 2026
New Primary Endpoint For Tetraplegia Drug Gets Support From Patients And The FDA
A conversation between NervGen CEO Adam Rogers and Clinical Leader Executive Editor Abby Proch. Spinal cord injury (SCI) has no…
For more
The Scientist
|
June 4, 2026
A New Approach to Treating Respiratory Attacks
Barry Quart from Connect Biopharma discusses the company’s dual-cytokine–targeting biologic that aims to treat acute asthma, chronic obstructive pulmonary disease…
For more
Fierce Pharma
|
June 3, 2026
Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US
As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the…
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
